Nakhle Saba, MD

Michael Wang, MD, and Nakhle Saba, MD, discuss how ongoing research is shaping the evolving role of BTK and BCL2 inhibitors in mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, discuss the management of adverse effects associated with BTK inhibition in mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, discuss data for the frontline combination of zanubrutinib, obinutuzumab, and venetoclax in mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, detail phase 1/2 findings for sonrotoclax in relapsed/refractory mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, discuss factors that drive BTK inhibitor selection in second-line mantle cell lymphoma.

Michael Wang, MD, and Nakhle Saba, MD, highlight current frontline treatment approaches for mantle cell lymphoma.